Neurocysticercosis treated with albendazole long term follow-up of a case.
The authors report a case of neurocysticercosis treated with Albendazole (methyl-5-propyl-thio-2-benzimidazilcarbamate). Computerized tomography (CT) and magnetic resonance imaging (MRI) of the brain presented various small bilateral parenchymal calcifications in the white matter and two inflammatory granulomatous formations localized respectively in the left and right posterior parietal lobe. After the serological diagnosis (Elisa-test) of cysticercosis, the patient was treated with albendazole (Zentel) with oral doses of 15 mg/kg/die for 20 days, and successively with a lower dose for another 40 days. Repeated CT and MRI showed a gradual reduction in the granulomas in comparison with the ones previously found, until the complete disappearance of the neuroradiological evidence of them. No side-effects were recorded during the treatment nor symptoms or neurological consequences in the period up until two years after the initial observation.
Maddalena
G
G
Neurological Division, Regional Hospital, Brindisi, Italy.
Nozzoli
C
C
Passarella
B
B
D015766:Albendazole / Q000627:therapeutic use*; D001927:Brain Diseases / Q000188:drug therapy* / Q000473:pathology; D003551:Cysticercosis / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D013997:Time Factors
D015766:Albendazole